Related Experiment Video
Updated: Aug 8, 2025
07:29
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.6K
Case Report of Histiocytoid Invasive Lobular Carcinoma.
Rebecca O Breese1, Kara Friend1
1Department of Surgery, Eastern Virginia Medical School, Norfolk, VA, USA.
The American Surgeon
|March 6, 2023
Summary
The rare histiocytoid variant of invasive lobular carcinoma (ILC) presents diagnostic challenges and aggressive behavior. This case shows rapid progression despite chemotherapy and immunotherapy.
Area of Science:
- Oncology
- Pathology
- Radiology
Background:
- Invasive lobular carcinoma (ILC) is the second most common type of invasive breast cancer.
- The histiocytoid variant is a rare subtype characterized by distinct cellular morphology.
- This variant is often associated with a poor prognosis and aggressive clinical course.
Observation:
- A 66-year-old female presented with a large, 6 cm mass, initially attributed to dense breast tissue.
- Diagnosis revealed invasive lobular carcinoma of the histiocytoid subtype with metastasis to axillary lymph nodes and vertebra.
- Despite initiating chemotherapy and immunotherapy, the patient developed new metastatic lesions in the spine, rib, and femur.
Findings:
- The histiocytoid variant of ILC demonstrated rapid progression and resistance to systemic therapy.
- Metastatic spread occurred extensively, involving multiple skeletal sites.
- The case underscores the aggressive nature and treatment challenges associated with this rare breast cancer subtype.
Implications:
- Early and accurate diagnosis of the histiocytoid variant is crucial for effective management.
- Novel therapeutic strategies may be required to overcome treatment resistance in aggressive ILC subtypes.
- Further research into the molecular mechanisms driving the aggressiveness of histiocytoid ILC is warranted.
